Bio Details

As chief medical officer of Pfizer, Dr. Rothenberg led Pfizer’s Worldwide Medical & Safety organization that is responsible for ensuring that patients, physicians, and regulatory agencies are provided with information on the safe and appropriate use of Pfizer’s medications. Dr. Rothenberg also served as a member of Pfizer’s Portfolio Strategy and Investment Committee, Worldwide Research, Development, and Medical Leadership Team, and Blueprint Leaders Forum. Prior to becoming Pfizer’s CMO, Dr. Rothenberg led Pfizer’s oncology clinical drug development efforts. Over a 10-year period, his team developed and obtained regulatory approvals for 11 new cancer medicines, including IBRANCE® (palbociclib), the first CDK 4/6 inhibitor for patients with HR+/HER2- advanced breast cancer, and XALKORI® (crizotinib), the first targeted medicine developed for patients with ALK+ non-small cell lung cancer. Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer for his success in cancer drug development, the Lane W. Adams Quality of Life Award from the American Cancer Society, and the Statesman Award from the American Society of Clinical Oncology. He received his BA magna cum laude from the University of Pennsylvania and his M.D. from the New York University School of Medicine. Dr. Rothenberg received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute.